Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100737
Status:
TERMINATED
Last Update Posted:
2006-02-06
First Post:
2005-01-06
Brief Title:
Comparing Interleukin-2 IL-2 Combined With Rituximab Rituxan to Rituximab Alone in Subjects With Non-Hodgkins Lymphoma NHL
Sponsor:
Chiron Corporation
Organization:
Chiron Corporation
Study Overview
Official Title:
A Phase 2 Randomized Open-Label Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin Rh-Interleukin-2 IL-2 to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkins Lymphoma Refractory or Relapsed After Previous Chemotherapy
Status:
TERMINATED
Status Verified Date:
2006-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None